Pks13-TE inhibitor 4, identified by its CAS number 3032947-26-2, is a synthetic compound that has garnered interest in the field of medicinal chemistry, particularly for its potential applications in treating bacterial infections. This compound functions as an inhibitor of the Pks13 enzyme, which is crucial for the biosynthesis of mycolic acids in the cell walls of mycobacteria, including Mycobacterium tuberculosis. The inhibition of Pks13 can disrupt the integrity of the bacterial cell wall, making it a promising target for antibiotic development. Characteristically, Pks13-TE inhibitor 4 may exhibit specific structural features that enhance its binding affinity to the target enzyme, potentially leading to improved efficacy against resistant strains of bacteria. Additionally, its pharmacokinetic properties, such as solubility, stability, and bioavailability, are critical for its development as a therapeutic agent. Ongoing research aims to further elucidate its mechanism of action, optimize its chemical structure, and evaluate its safety and effectiveness in clinical settings.

Pks13-TE inhibitor 4

3032947-26-2: Pks13-TE inhibitor 4, identified by its CAS number 3032947-26-2, is a synthetic compound that has garnered interest in the field of medicinal chemistry, particularly for its potential applications in treating bacterial infections. This compound functions as an inhibitor of the Pks13 enzyme, which is crucial for the biosynthesis of mycolic acids in the cell walls of mycobacteria, including Mycobacterium tuberculosis. The inhibition of Pks13 can disrupt the integrity of the bacterial cell wall, making it a promising target for antibiotic development. Characteristically, Pks13-TE inhibitor 4 may exhibit specific structural features that enhance its binding affinity to the target enzyme, potentially leading to improved efficacy against resistant strains of bacteria. Additionally, its pharmacokinetic properties, such as solubility, stability, and bioavailability, are critical for its development as a therapeutic agent. Ongoing research aims to further elucidate its mechanism of action, optimize its chemical structure, and evaluate its safety and effectiveness in clinical settings.

<p>Pks13-TE inhibitor 4 (compound 44) is a potent inhibitor from the thiazole series that effectively targets Pks13 to combat tuberculosis (TB) and addresses drug resistance.</p>

CAS 3032947-26-2

Pks13-TE inhibitor 4

Pks13-TE inhibitor 4

Ref: TM-T208278